Find and Join

News Logo

• APC best practices presented at ketamine forum

  APC CEO Scott Brunner and PCCA’s A.J. Day attended a forum in Washington, D.C., on the emergence of ketamine as an area of therapeutic interest. read more →

• APC weighs in with several state BOPs

  APC is always keeping track of what state boards of pharmacy are up to, and we’ll reach out when we think something needs clarification. Here’s a sampling of the kind of letters we’ve sent recently. read more →

• Success: Town hall briefing on GLP-1 compounding

  We blasted through our expectations for our virtual town hall on compounding semaglutide on June 26, with almost 700 people registered. read more →

• APC delivers compounding briefing on Capitol Hill

  APC briefed about four dozen House of Representatives healthcare staffers on the practice of pharmacy compounding — and cleared some of the muddied waters. read more →

• Those Lilly letters

  We learned this week that several compounding pharmacies have received a cease-and-desist letter from a law firm representing Eli Lilly. read more →

• CCH registration is OPEN!

  Demonstrate your commitment to your patients and practice at APC’s annual DC fly-in for pharmacy compounders, September 17-18 at Hilton National Mall. read more →

More News

Fagron Ad

Blank

PCCA Ad

Blank

Medisca Ad

Blank

TopiClick Ad

Blank

Wedgewood Ad

APC CEO Scott Brunner and PCCA’s A.J. Day attended a forum in Washington, D.C., on the emergence of ketamine as an area of therapeutic interest, sponsored by the Reagan-Udall Foundation for the FDA. The best part: AJ was part of a panel discussion regarding APC’s ketamine compounding best practices document.